PRLD
PRLD
NASDAQ · Biotechnology

Prelude Therapeutics Inc

$3.65
+0.23 (+6.73%)
As of Apr 1, 2:56 PM ET ·
Financial Highlights (FY 2026)
Revenue
10.26M
Net Income
-84,049,736
Gross Margin
Profit Margin
-819.6%
Rev Growth
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 44.6% 44.6% 44.6%
Operating Margin -861.3% 2.4% 2.2% 2.0%
Profit Margin -819.6% 2.1% 2.1% 1.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 10.26M 132.26M 127.36M 112.48M
Gross Profit 59.02M 56.83M 50.19M
Operating Income -88,358,426 3.13M 2.80M 2.22M
Net Income -84,049,736 2.80M 2.65M 2.17M
Gross Margin 44.6% 44.6% 44.6%
Operating Margin -861.3% 2.4% 2.2% 2.0%
Profit Margin -819.6% 2.1% 2.1% 1.9%
Rev Growth +3.8% -1.6% +5.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 48.17M 45.92M 54.82M
Total Equity 75.94M 77.37M 76.22M
D/E Ratio 0.63 0.59 0.72
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -82,606,543 4.42M 4.16M 3.31M
Free Cash Flow 2.17M 2.21M 2.87M